26 results on '"Ricci V."'
Search Results
2. An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients
3. PD-009 Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: a pooled analysis of GONO studies
4. EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle
5. Correlation between values of specific biomarkers and outcome in metastatic colorectal cancer patients treated with regorafenib
6. FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in mCRC: Final results of the phase II randomized MOMA trial by GONO
7. Predictive value of CT texture analysis in lung cancer patients undergoing nivolumab
8. P-140 - Correlation between values of specific biomarkers and outcome in metastatic colorectal cancer patients treated with regorafenib
9. Tumor-infiltrating lymphocytes (TILs) density as prognostic determinant in stage II colorectal cancer
10. Tumor-infiltrating lymphocytes (tils) density as prognostic determinant in stage ii colorectal cancer
11. Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: a pooled analysis of GONO studies
12. Metronomic oral cyclophosphamide (CTX) in patients (pts) with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC)
13. P-030 Tumor-infiltrating lymphocytes (TILs) density as prognostic determinant in stage II colorectal cancer
14. O-017 - FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in mCRC: Final results of the phase II randomized MOMA trial by GONO
15. Retrospective evaluation of ADCC activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients (mCRC)
16. P-235 Retrospective evaluation of ADCC activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients (mCRC)
17. 75P - Predictive value of CT texture analysis in lung cancer patients undergoing nivolumab
18. Folfoxiri Plus Bevacizumab (Bev) As First-Line Treatment of Ras Wild-Type (Wt) Metastatic Colorectal Cancer (Mcrc) Patients (Pts)
19. Pharmacogenetic Profiling for Toxicity of Oxaliplatin and Fluoropyrimidines. Final Report from an Ancillary Protocol to the Tosca (Three or Six Colon Adjuvant) Trial
20. 572P - Tumor-infiltrating lymphocytes (TILs) density as prognostic determinant in stage II colorectal cancer
21. D14 - Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: a pooled analysis of GONO studies
22. D21 - Tumor-infiltrating lymphocytes (tils) density as prognostic determinant in stage ii colorectal cancer
23. C29 - Metronomic oral cyclophosphamide (CTX) in patients (pts) with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC)
24. E14 - Retrospective evaluation of ADCC activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients (mCRC)
25. 576P - Pharmacogenetic Profiling for Toxicity of Oxaliplatin and Fluoropyrimidines. Final Report from an Ancillary Protocol to the Tosca (Three or Six Colon Adjuvant) Trial
26. 517P - Folfoxiri Plus Bevacizumab (Bev) As First-Line Treatment of Ras Wild-Type (Wt) Metastatic Colorectal Cancer (Mcrc) Patients (Pts)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.